DECEMBER 20246LIFE SCIENCES REVIEWThe field of genetic testing, particularly whole genome sequencing (WGS), is undergoing rapid transformation. As the global market for Next-Generation Sequencing (NGS) is projected to experience substantial growth by 2030, advancements in technology and accessibility are driving innovation. The most significant factor behind this expansion is the continuous reduction in sequencing costs, making genetic testing more affordable and practical, especially in diagnosing rare diseases.Another prominent trend is the rise of clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing technologies, which are advancing from research to therapeutic applications. The focus has shifted from simple gene editing to more precise and complex modifications, enabling breakthroughs in areas such as cancer treatment, rare genetic diseases and agricultural biotechnology. In the APAC region, countries like China, Japan and South Korea are leading in clinical trials involving CRISPR technology, pushing the boundaries of gene therapies and precision medicine. With regulatory bodies becoming more receptive to these innovations, the APAC region is positioned to play a pivotal role in the global genomics market.Driven by these trends, the global genomics market is poised to reach $83.1 billion by 2028, growing at a CAGR of 12.4 percent from 2023 to 2028.In this edition of Life Sciences Review APAC, we provide insights into recent developments in the life science market and how companies offer services aligned with the latest trends.The magazine features a thought leadership article from Prue Cowin B. BiomedSci (Hons) PhD, Senior Associate, Patent Attorney, Partner, FB Rice and Dr. Sarah Tregenza BSc (Hons) PhD, APAC Oncology Medical Affairs Director, Pierre Fabre, who highlights the evolution of cancer treatment from non-specific therapies to highly targeted approaches like CAR-T cell therapy and the importance of patent strategy for companies in this field. It also features an article from Jesper Lekdorf, MD, Senior Director, Head of NSCD Commercialisation Unit, MASH, CVD, Cell Therapy & Alzheimer's Disease, Novo Nordisk Japan, who sheds light on the significant advancements in insulin treatment for people with diabetes, from the early days of purified pancreatic extracts to modern recombinant DNA technology and engineered insulin molecules.We also bring you the story of the top genomics service providing companies that are at the forefront of breakthroughs. One of them is Alpha IVF Group, which excels in advanced fertility treatments, including IVF, preimplantation genetic testing and AI-enhanced embryo selection.In this edition featuring the Top Genomics Solutions Providers in APAC 2024, we hope you find the right partner to meet your organization's needs.Let us know your thoughts!EDITORIALUnleashing the Power of GenomicsCopyright © 2024 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Email:sales@lifesciencesreview.comeditor@lifesciencesreview.commarketing@lifesciencesreview.com DECEMBER - 12 - 2024, Vol 05, Issue - 46 (ISSN 2831-8331) Published by ValleyMedia, Inc.To subscribe to Life Sciences ReviewVisit www.lifesciencesreview.com Editorial StaffAaron PierceCarolynn WaltersShirley FaithRussell ThomasVisualizerPresley MeadowDisclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsJeremy WilliamsManaging Editoreditor@lifesciencesreview.comManaging EditorJeremy WilliamsHenry SmithClara Matthew
< Page 5 | Page 7 >